文档介绍：Power of Two 企业如何选择适合自己的“重磅炸弹” Bill Guo 国际知名企业如何开展新药/通用名药的研究 葛兰素史克 Dr Reddy’s Lab Venturepharm Fast Facts: FY 2002 (April 1 – March 31) Sales: $340 million Net Profit: $101 million EPS: $ Cash Reserve: $120 million Market Capitalization: $ billion (9/18/02) Shares Outstanding: million A Record of Achievement: First Asia/Pacific* company listed on NYSE, April 2001: RDY First India-pany to: Receive 180-day exclusivity for generic drug in the . File an NDA under Sec. 505(b)(2) (amlodipine maleate) License an NCE to a multinational firm *Excluding Japan An Emerging Pharmaceutical Firm Key Research Facilities Aurigene Discovery Technologies (Boston) Bangalore Labs/ Aurigene* (Bangalore) . Therapeutics (Atlanta) Dr. Reddy’s Research Foundation Technology Development Center *December 2002 Drug Discovery Scientists: 260 Process Research Center Discovery Research Process Research Discovery Services Center Strategic Overview *Less Regulated Market New Chemical Entities Longer-Term Specialty Rx Mid-Term Generics Near-Term Branded Generics* Active Pharmaceutical Ingredients Base Business Time Driving Value Pain Management DRF 4848 Phase I Phase II Phase III Pre-clinical Trials Clinical Trials Metabolic Disorders DRF 4832 DRF 4158 * * Licensed to Novartis Cancer DRF 3188 DRF 1644 DRF 1042 Diabetes DRF NPPC DRF 2593 DRF 27251 ** Licensed to Novo Nordisk ** ** 1Development status to be determined Q1/2003 NCE Pipeline: Driving Growth Longer-Term